Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px

News > All

Total search results: 3657 | Ordered by Source (ascending)
1 2 3 ... 35 36 37  next pagenext page

order ascendingorder descendingSource order ascendingorder descendingDate
10x Genomics Inc.. (2/24/21). "Press Release: 10x Genomics Showcases Next Wave of Innovations at First Ever Xperience Event. Acquires Tetramer Shop, Reveals Details on Upcoming Products". Pleasanton, CA. 2021-02-24
3B Pharmaceuticals GmbH. (4/24/23). "Press Release: 3B Pharmaceuticals Enters into a Global Exclusive Licensing Agreement for its FAP-Targeting Peptide Technology". Berlin. 2023-04-24
3D Systems, Inc.. (2/23/22). "Press Release: 3D Systems to Expand Healthcare Applications Portfolio with Acquisition of Kumovis". Rock Hill, SC. 2022-02-23
4basebio AG. (7/28/20). "Press Release: 4basebio Informs about Takeover Bid by Sparta AG". Heidelberg & Cambridge. 2020-07-28
4D Lifetec AG. (10/18/23). "Press Release: 4D Lifetec Secures CHF 23.3 Mio in a Share and Investment Deal with Xlife Sciences Opening New Horizons in Using AI and Digital Health in Early Cancer Detection". Zürich & Cham. 2023-10-18
4D Lifetec AG. (7/11/22). "Press Release: 4D Lifetec Announces Successful First closing of CHF 1.9 Million Series B Financing to Launch Its Early Lung Cancer Detection Liquid Biopsy Assay 4D Lifetest Lung Dx in Europe". Cham. 2022-07-11
4SC AG. (10/18/23). "Press Release: 4SC Receives Orphan Drug Designation (ODD) for Resminostat (Kinselby) in CTCL in the European Union". Planegg-Martinsried. 2023-10-18
4SC AG. (11/12/19). "Press Release: 4SC AG Secures circa EUR 22.4 Million from a Capital Increase [Not for release in US, Australia, Canada, et al.]". Planegg-Martinsried. 2019-11-12
4SC AG. (11/25/20). "Press Release: 4SC AG Resolves to Issue New Shares with Expected Proceeds of approx. EUR 7.5 Million (ad hoc) [not for US, AU, CA, JP, ZA, et al.]". Planegg-Martinsried. 2020-11-25
4SC AG. (2/6/19). "Press Release: First Patient Enrolled in Phase II Study EMERGE of Domatinostat (4SC-202) in Gastrointestinal Cancer". Planegg-Martinsried. 2019-02-06
4SC AG. (3/20/19). "Press Release: 4SC AG Provides Results for Financial Year 2018 and Outlook". Planegg-Martinsried. 2019-03-20
4SC AG. (6/28/19). "Press Release: 4SC AG Secures EUR 11 Million from Capital Increase [Ad hoc, not for US, AU, CA, JP, ZA, et al.]". Planegg-Martinsried. 2019-06-28
4SC AG. (9/11/20). "Press Release: 4SC and Maruho Discontinue Collaboration for Development of 4SC’s Kv1.3 Inhibitors". Planegg-Martinsried. 2020-09-11
4SC AG. (9/27/23). "Press Release: 4SC Receives Orphan Drug Designation (ODD) for Resminostat (Kinselby) in CTCL from the US FDA". Planegg-Martinsried. 2023-09-27
4Teen4 Pharmaceuticals GmbH. (12/5/19). "Press Release: Biotech Startup 4Teen4 Pharmaceuticals Closes EUR 7 Million Series A Financing". Hennigsdorf. 2019-12-05
908 Devices, Inc.. (6/22/21). "Press Release: 908 Devices Announces New Data Integrations with Key Industry Partners to Accelerate BioProcess Data Insights". Boston, MA. 2021-06-22
908 Devices, Inc.. (6/3/19). "Press Release: 908 Devices Broadens the ZipChip Platform, Brings New Capability to Biotherapeutics Researchers". Boston, MA. 2019-06-03
908 Devices, Inc.. (7/25/19). "Press Release: 908 Devices Poised to Modernize Upstream Bioprocess Analytics with a Grant from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)". Boston, MA. 2019-07-25
908 Devices, Inc.. (8/9/22). "Press Release: 908 Devices Acquires Trace Analytics, Enabling On-line Bioanalytics". Boston, MA. 2022-08-09
A2 Biotherapeutics, Inc.. (10/6/20). "Press Release: A2 Biotherapeutics Closes $71.5m Series B to Begin Clinical Development of Its Potentially TransformativeSelective Tumor Cell Therapeutics". Agoura Hills, CA. 2020-10-06
A2 Biotherapeutics, Inc.. (11/5/19). "Press Release: A2 Biotherapeutics Emerges from Stealth Mode with $57m Series A to Develop a Pipeline of Selective Tumor Cell Therapeutics". Agoura Hills, CA. 2019-11-05
AATec Medical GmbH. (10/31/23). "Press Release: AATec Medical and Beurer Enter Development Collaboration for Inhaled Alpha-1 Antitrypsin". Munich. 2023-10-31
AATec Medical GmbH. (7/17/23). "Press Release: AATec Medical Announces Its Launch with EUR 2.7 Million in Seed Financing to Unlock the Therapeutic Potential of Alpha-1 Antitrypsin". Munich. 2023-07-17
AaviGen GmbH. (7/26/23). "Press Release: AaviGen Raises 17 Million € in Second Financing Round to Advance Precision Gene Therapies for Heart Failure towards the Clinical Stage". Heidelberg. 2023-07-26
Abalos Therapeutics GmbH. (10/14/21). "Press Release: Abalos Therapeutics Completes Series A Extension Bringing Total Raised to EUR 43 Million". Düsseldorf. 2021-10-14
Abalos Therapeutics GmbH. (10/15/19). "Press Release: Abalos Therapeutics Launches with €12M Series A Round to Develop Novel Immuno-Virotherapies Against Cancer". Essen. 2019-10-15
AbbVie Inc.. (1/25/19). "Press Release: AbbVie Reports Full-Year and Fourth-Quarter 2018 Financial Results". North Chicago, IL. 2019-01-25
AbbVie Inc.. (6/25/19). "Press Release: AbbVie to Acquire Allergan in Transformative Move for Both Companies". 2019-06-25
AbCellera Biologics, Inc.. (2/14/19). "Press Release: AbCellera Announces Multi-Target Partnership Agreement with a Top 5 Global Pharma". Vancouver, BC. 2019-02-14
Abingworth LLP. (2/3/21). "Press Release: Abingworth Raises $465m for New Life Sciences Fund Abingworth Bioventures 8". London. 2021-02-03
Abionic S.A.. (9/13/19). "Press Release: International Pivotal Study Successfully Demonstrates Diagnosis of Sepsis within 5 Minutes – 24 Hours Earlier Compared with Current Standard-of-Care". Lausanne. 2019-09-13
Abionic S.A.. (9/5/19). "Press Release: Abionic Signs Agreement to Optimize Asthma Management in the U.S. through Innovative Rapid Point-of-Care Tests". Lausanne. 2019-09-05
Abivax S.A.. (3/14/19). "Press Release: Abivax 2018 Financial Results and Operations Update". Paris. 2019-03-14
Abivax S.A.. (8/23/23). "Press Release: Abivax Appoints Patrick Malloy as Senior Vice President Investor Relations". Paris. 2023-08-23
AC Immune S.A.. (1/30/19). "Press Release: AC Immune Reports Discontinuation of Phase III CREAD 1 and 2 Studies of Crenezumab in Alzheimer’s Disease". Lausanne. 2019-01-30
AC Immune S.A.. (12/15/23). "Press Release: AC Immune Announces Pricing of Underwritten Offering of Common Shares". Lausanne. 2023-12-15
AC Immune S.A.. (12/15/23). "Press Release: AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO". Lausanne. 2023-12-15
AC Immune S.A.. (3/21/19). "Press Release: AC Immune Reports Full-Year 2018 Financial Results and Provides Business Update". Lausanne. 2019-03-21
AC Immune S.A.. (3/23/20). "Press Release: AC Immune Receives Second Milestone and New Milestone to Increase the Potential Deal Value of Lilly Morphomer Tau Partnership". Lausanne. 2020-03-23
AC Immune S.A.. (5/13/24). "Press Release: AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease". Osaka, Cambride, MA & Lausanne. 2024-05-13
AC Immune S.A.. (6/27/23). "Press Release: AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease". Lausanne. 2023-06-27
AC Immune S.A.. (7/27/21). "Press Release: AC Immune Announces Strategic Acquisition of Industry-leading Parkinson’s Disease Vaccine Candidate and Equity Investment Led by Athos Service GmbH". Lausanne. 2021-07-27
AC Immune S.A.. (8/12/19). "Press Release: AC Immune Announces Research Collaboration with University of Pennsylvania Focusing on Pathogenic Protein TDP-43 in Neurodegenerative Diseases". Lausanne. 2019-08-12
AC Immune S.A.. (8/5/20). "Press Release: AC Immune Reports Q2 2020 Financial Results and Provides Business Update". Lausanne. 2020-08-05
AC Immune S.A.. (9/17/19). "Press Release: AC Immune Receives Milestone Payment in Connection with Initiation of a Phase 2 Trial of Tau PET Tracer PI-2620". Lausanne. 2019-09-17
AC Immune S.A.. (9/20/19). "Press Release: AC Immune Receives First Milestone Payment from Lilly in Small Molecule Tau Morphomer Program". Lausanne. 2019-09-20
AC Immune S.A.. (9/4/19). "Press Release: AC Immune Awarded Michael J. Fox Foundation Grant to Accelerate Development of Parkinson’s Disease Diagnostic Imaging Agent". Lausanne. 2019-09-04
ActiTrexx GmbH. (3/2/21). "Press Release: Newly Founded Biotech Company ActiTrexx Receives Funding of € 3.5 Million to Develop Cell Therapy against Transplant Rejection". Mainz. 2021-03-02
Adapsyn Bioscience Inc.. (9/21/22). "Press Release: Adapsyn Bioscience Enters into Strategic Collaboration with Evotec". Hamilton, ON. 2022-09-21
ADC Therapeutics S.A.. (1/16/19). "Press Release: ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors". Lausanne. 2019-01-16
ADC Therapeutics S.A.. (1/18/22). "Press Release: ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize Zynlonta(loncastuximab tesirine-lpyl) in Japan". Lausanne. 2022-01-18
ADC Therapeutics S.A.. (1/3/19). "Press Release: ADC Therapeutics to Appoint Peter Hug, Ph.D., to Board of Directors". Lausanne. 2019-01-03
ADC Therapeutics S.A.. (1/4/19). "Press Release: ADC Therapeutics Doses First Patient in Phase Ib Clinical Trial of ADCT-301 in Patients with Advanced Solid Tumors". Lausanne. 2019-01-04
ADC Therapeutics S.A.. (1/4/23). "Press Release: ADC Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference". Lausanne. 2023-01-04
ADC Therapeutics S.A.. (10/2/19). "Press Release: ADC Therapeutics Announces Withdrawal of Registration Statement". Lausanne. 2019-10-02
ADC Therapeutics S.A.. (11/1/22). "Press Release: ADC Therapeutics Appoints Kristen Harrington-Smith as Chief Commercial Officer and Peter Graham as Chief Legal Officer". Lausanne. 2022-11-01
ADC Therapeutics S.A.. (11/5/19). "Press Release: ADC Therapeutics Appoints Jennifer Herron as Chief Commercial Officer". Lausanne. 2019-11-05
ADC Therapeutics S.A.. (12/14/20). "Press Release: ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma to Develop and Commercialize Lonca and other ADCs for Hematologic and Solid Tumor Indications in Greater China 2020-12-14
ADC Therapeutics S.A.. (12/19/22). "Press Release: ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer". Lausanne. 2022-12-19
ADC Therapeutics S.A.. (12/21/22). "Press Release: ADC Therapeutics and Sobi Announce European Commission Approval of Zynlonta (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma". Lausanne. 2022-12-21
ADC Therapeutics S.A.. (2/13/19). "Press Release: ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-402 (loncastuximab tesirine) and Imfinzi (durvalumab) in Multiple Types of Advanced Non-Hodgkin Lymphoma". Lausanne. 2019-02-13
ADC Therapeutics S.A.. (2/20/19). "Press Release: ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-402 (loncastuximab tesirine) and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma" 2019-02-20
ADC Therapeutics S.A.. (3/19/20). "Press Release: ADC Therapeutics to Appoint Ron Squarer as Chairman of Its Board of Directors and an Advisor to the Company". Lausanne. 2020-03-19
ADC Therapeutics S.A.. (4/21/20). "Press Release: ADC Therapeutics Appoints Jennifer Creel as Chief Financial Officer". Lausanne. 2020-04-21
ADC Therapeutics S.A.. (4/24/19). "Press Release: ADC Therapeutics and Adagene Announce License Agreement". Lausanne & Suzhou. 2019-04-24
ADC Therapeutics S.A.. (4/24/20). "Press Release: ADC Therapeutics Files Registration Statement for Proposed Initial Public Offering". Lausanne. 2020-04-24
ADC Therapeutics S.A.. (4/27/20). "Press Release: ADC Therapeutics Appoints Victor Sandor, M.D., to Its Board of Directors". Lausanne. 2020-04-27
ADC Therapeutics S.A.. (4/6/21). "Press Release: Overland ADCT BioPharma Appoints Eric Koo as Chief Executive Officer". Boston, MA, Shanghai & Lausanne. 2021-04-06
ADC Therapeutics S.A.. (5/1/20). "Press Release: ADC Therapeutics Announces a $115 Million Convertible Credit Facility with Deerfield". Lausanne. 2020-05-01
ADC Therapeutics S.A.. (5/11/20). "Press Release: ADC Therapeutics Announces Launch of Initial Public Offering". Lausanne. 2020-05-11
ADC Therapeutics S.A.. (5/6/24). "Press Release: ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants". Lausanne. 2024-05-06
ADC Therapeutics S.A.. (5/9/22). "Press Release: ADC Therapeutics Announces CEO Transition. Co-Founder Chris Martin Transitions CEO Role to Industry Veteran Ameet Mallik". Lausanne. 2022-05-09
ADC Therapeutics S.A.. (6/12/19). "Press Release: ADC Therapeutics Announces Completion of a Series E Financing Expansion. Brings Total Raised in the Series E Round to $276 Million". Lausanne. 2019-06-12
ADC Therapeutics S.A.. (6/13/22). "Press Release: ADC Therapeutics Names David Gilman as Chief Business & Strategy Officer". Lausanne. 2022-06-13
ADC Therapeutics S.A.. (6/29/22). "Press Release: ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of Zynlonta (loncastuximab tesirine-lpyl) in Combination with Other Anti-cancer Agents". Lausanne. 2022-06-29
ADC Therapeutics S.A.. (7/1/22). "Press Release: ADC Therapeutics Appoints Jean-Pierre Bizzari, MD, to Board of Directors". Lausanne. 2022-07-01
ADC Therapeutics S.A.. (7/20/23). "Press Release: ADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of Zynlonta (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients". Lausanne. 2023-07-20
ADC Therapeutics S.A.. (7/8/22). "Press Release: ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize Zynlonta (loncastuximab tesirine-lpyl) in Europe and Select International Territories". Lausanne. 2022-07-08
ADC Therapeutics S.A.. (7/9/19). "Press Release: ADC Therapeutics Announces Final Close of Series E Financing Expansion". Lausanne. 2019-07-09
ADC Therapeutics S.A.. (8/15/22). "Press Release: ADC Therapeutics Announces $175 Million Senior Secured Term Loan from Owl Rock and Oaktree and Settlement of Existing Senior Secured Convertible Notes". Lausanne. 2022-08-15
ADC Therapeutics S.A.. (8/26/19). "Press Release: ADC Therapeutics and Freenome Enter Biomarker Development Collaboration". Lausanne & South San Francisco, CA. 2019-08-26
ADC Therapeutics S.A.. (8/26/21). "Press Release: ADC Therapeutics Enters Into a Financing Agreement with HealthCare Royalty for Up to $325 Million". Lausanne. 2021-08-26
ADC Therapeutics S.A.. (8/3/21). "Press Release: ADC Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates". Lausanne. 2021-08-03
ADC Therapeutics S.A.. (8/6/19). "Press Release: ADC Therapeutics and Sophia Genetics Partner for Biomarker Discovery in Pivotal Phase II Clinical Trial". Lausanne. 2019-08-06
ADC Therapeutics S.A.. (9/23/19). "Press Release: ADC Therapeutics Announces Launch of Initial Public Offering". Lausanne. 2019-09-23
ADC Therapeutics S.A.. (9/6/19). "Press Release: ADC Therapeutics Files Registration Statement for Proposed Initial Public Offering". Lausanne. 2019-09-06
ADC Therapeutics S.A.. (9/6/22). "Press Release: ADC Therapeutics to Participate in Morgan Stanley’s 20th Annual Global Healthcare Conference". Lausanne. 2022-09-06
Adcendo ApS. (7/6/21). "Press Release: Adcendo Appoints Michael Pehl as Chief Executive Officer". 2021-07-06
Addex Therapeutics S.A.. (1/11/21). "Press Release: Addex Successfully Completes $11.5 Million Capital Increase Including Full Exercise of Underwriter’s Option to Purchase Additional Securities". Geneva. 2021-01-11
Addex Therapeutics S.A.. (4/29/24). "Press Release: Addex Provides Update on ADX71149 Phase 2 Epilepsy Study". Geneva. 2024-04-29
Addex Therapeutics S.A.. (4/3/24). "Press Release: Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders". Geneva & New York, NY. 2024-04-03
Addex Therapeutics S.A.. (8/27/20). "Press Release: Addex and the SIB Swiss Institute of Bioinformatics Receive Innosuisse Grant to Repurpose Potent Dopamine Antagonist Using Computational Modelling". Geneva. 2020-08-27
Addex Therapeutics S.A.. (9/24/19). "Press Release: Addex Therapeutics Submits Registration Statement with the U.S. SEC to Facilitate Nasdaq Listing of ADSs Representing Shares". Geneva. 2019-09-24
Adeptrix Corporation. (1/6/21). "Press Release: Adeptrix Closes Series A Financing to Commercialize BAMS Bioanalytical Reagents for Life Science Research". Beverly, MA. 2021-01-06
Adivo GmbH. (9/15/23). "Press Release: Adivo Joins Zoetis to Bring the Benefits of Species-specific Antibody Therapies to Pet Owners Worldwide". Puchheim & Munich. 2023-09-15
Adrenomed AG. (1/4/21). "Press Release: Adrenomed Supervisory Board Appoints Dr. Wolfgang Baiker as CEO". Hennigsdorf. 2021-01-04
Adrenomed AG. (11/30/20). "Press Release: Adrenomed Closes EUR 22 Million Equity Financing to Accelerate Development of Adrecizumab (HAM8101) and Provides Business Update". Hennigsdorf. 2020-11-30
Adrenomed AG. (2/21/20). "Press Release: Adrenomed Announces Positive Top-Line AdrenOSS-2 Phase II Results with Adrecizumab in Septic Shock". Hennigsdorf. 2020-02-21
Adrenomed AG. (3/15/22). "Press Release: Adrenomed Supervisory Board Appoints Dr. Richard Jones as CEO". Hennigsdorf. 2022-03-15
Adrenomed AG. (4/10/24). "Press Release: AdrenoMed Receives FDA Fast Track Designation for Enibarcimab for Treatment of Septic Shock". Hennigsdorf. 2024-04-10
1 2 3 ... 35 36 37  next pagenext page



Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group World of Partnering Opportunities 650x300px

» top